Cantai Therapeutics
Philadelpia, US · Founded 2023 · Delaware corporation · 5 employees on LinkedIn · 4 known investors
Find your way into Cantai Therapeutics
398 people in our graph share verified history with the Cantai Therapeutics team — schools, employers, funds. One of them is your warm intro.
Ren Rileyunlockedknows Errik Anderson · together at Dartmouth College (overlapped)
knows the team · via Dartmouth College
×3knows the team · via Alumni Ventures
×2knows the team · via Welbe Health
knows the team · via Strawberry Creek Ventures
knows the team · via Ulysses Diversified Holdings
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease. The company operates in the therapeutics and biotech space.
Founders & leadership
Cantai Therapeutics was founded in 2023 by Errik Anderson.
EA
Errik AndersoninFounderErrik Anderson is Executive Officer and Director at Cantai Therapeutics, a biotech company developing bispecific antibodies for autoimmune disease.
RL
Board
JB
Joshua BrandtBoard director
GV
Investors · 4
Also in the syndicate · 2
Tellus BioTellus BioVentures
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 3 rounds · 2023–2026
▶$3MraisedJan 2026 · 3 investors · BiotechnologyRule 506(b)
▶$3MraisedJan 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ross LeimbergExecutive Officer, Director
- Errik B. AndersonExecutive Officer
- Getta VemuriExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$550KraisedJul 2025 · 3 investors · BiotechnologyRule 506(b)
▶$550KraisedJul 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joshua BrandtDirector
- Errik AndersonExecutive Officer, Director
- Ross LeimbergExecutive Officer, Director
- Geeta VemuriExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $550K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$700KraisedNov 2023 · 3 investors · BiotechnologyRule 506(b)
▶$700KraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geeta VemuriExecutive Officer, Director
- Errik AndersonExecutive Officer, Director
- Ross LeimbergExecutive Officer
- Joshua BrandtExecutive Officer
- Offering amount
- $3M
- Amount sold
- $700K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Cantai Therapeutics went on to found or lead other companies.
Competitors · 4
by search overlap
Montai Therapeutics5 shared keywordsMontai is a drug discovery company that combines human biology, chemistry, computational biology, and machine learning to identify connections between chemistry and disease pathways and develop new therapies. It focuses on treating chronic diseases and aims to partner with industry to advance therapies for patients and clinicians.
flagship pioneering5 shared keywordsFlagship Pioneering is a firm that builds and funds companies in life sciences and related fields, describing itself as focused on breakthroughs for people and the planet.
Alloy5 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
NVIDIA3 shared keywordsNVIDIA designs GPUs, AI computing hardware, and software platforms for AI development, data centers, autonomous vehicles, and robotics, serving developers, researchers, and enterprises. Its offerings include AI models, power architecture for AI factories, and compute infrastructure used across industries such as manufacturing, healthcare, and automotive.
Companies competing with Cantai Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cantai Therapeutics do?
- Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease. The company operates in the therapeutics and biotech space.
- Who founded Cantai Therapeutics?
- Cantai Therapeutics was founded by Errik Anderson in 2023.
- Who are Cantai Therapeutics's investors?
- Cantai Therapeutics's investors include Agent Capital, 82VS.
- How much funding has Cantai Therapeutics raised?
- Cantai Therapeutics has disclosed $4.3M raised across 3 rounds.
- Where is Cantai Therapeutics headquartered?
- Cantai Therapeutics is headquartered in Philadelpia, US.